Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Founded in 2005, we are a Nevada corporation that designs, develops, and markets exoskeleton products that augment human strength, endurance and mobility. The primary end market for our exoskeleton technology is healthcare, where our technology primarily serves people with physical disabilities or impairments in both physical rehabilitation and mobility.
The business is unprofitable at the operating level (-104.12% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 28.6% YoY. Margins deteriorated 45.8pp alongside, both lines moving the wrong way.
ROIC dropped from -55.50% to -81.92%, capital efficiency is deteriorating. Negative free cash flow of -$12M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$11M
▼ -28.6% YoY
Net Income (TTM)
-$16M
▼ -3.2% YoY
Op. Margin
-137.67%
▼ -45.8pp YoY
ROIC
-321.31%
▼ -26.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$12M
▼ -21.3% YoY
Op. Cash Flow (TTM)
-$12M
▼ -19.9% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$4M
5Y CAGR: +7.6%
Continue Research